相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effect of Food or Proton Pump Inhibitor Treatment on the Bioavailability of Dacomitinib in Healthy Volunteers
Ana Ruiz-Garcia et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial
Stefano Maria Magrini et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Cancer Statistics, 2015
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib
Nagdeep Giri et al.
INVESTIGATIONAL NEW DRUGS (2015)
Pharmacokinetic assessment of dacomitinib (pan-HER tyrosine kinase inhibitor) in patients with locally advanced head and neck squamous cell carcinoma (LA SCCHN) following administration through a gastrostomy feeding tube (GT)
Joanne W. Chiu et al.
INVESTIGATIONAL NEW DRUGS (2015)
Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma
Maura L. Gillison et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study
Kevin Harrington et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Genetic Landscape of Human Papillomavirus-Associated Head and Neck Cancer and Comparison to Tobacco-Related Tumors
D. Neil Hayes et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Human Papillomavirus-Negative Pharyngeal Cancer
Magnus T. Dillon et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
Jean-Pascal H. Machiels et al.
LANCET ONCOLOGY (2015)
Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck
Han Sang Kim et al.
CLINICAL CANCER RESEARCH (2015)
Recurrent and second primary squamous cell carcinoma of the head and neck: When and how to reirradiate
Primoz Strojan et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2015)
Challenges in EGFRvIII Detection in Head and Neck Squamous Cell Carcinoma
Sarah E. Wheeler et al.
PLOS ONE (2015)
Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial
J. B. Vermorken et al.
ANNALS OF ONCOLOGY (2014)
Assessment of Erlotinib as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer Patients
Eben L. Rosenthal et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
Chemoprevention of Head and Neck Cancer with Celecoxib and Erlotinib: Results of a Phase Ib and Pharmacokinetic
Nabil F. Saba et al.
CANCER PREVENTION RESEARCH (2014)
Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC)
Roger B. Cohen
CANCER TREATMENT REVIEWS (2014)
Head and Neck Squamous Cell Carcinomas Do Not Express EGFRvIII
Lieuwe J. Melchers et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522
K. Kian Ang et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
A Phase I Open-Label Study to Investigate the Potential Drug-Drug Interaction Between Single-Dose Dacomitinib and Steady- State Paroxetine in Healthy Volunteers
Ana Ruiz-Garcia et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non-Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib or Gefitinib A Phase I/II Trial
Keunchil Park et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial
Peter M. Ellis et al.
LANCET ONCOLOGY (2014)
Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial
Suresh S. Ramalingam et al.
LANCET ONCOLOGY (2014)
Concomitant platinum-based chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer: A systematic review and meta-analysis of published studies
Fausto Petrelli et al.
ORAL ONCOLOGY (2014)
Targeting the epidermal growth factor receptor for head and neck cancer chemoprevention
Milena P. Mak et al.
ORAL ONCOLOGY (2014)
Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: A randomized, open-label, phase IIb, 5-year study in Indian patients
B. K. M. Reddy et al.
ORAL ONCOLOGY (2014)
Pre-Clinical Characterization of Dacomitinib (PF-00299804), an Irreversible Pan-ErbB Inhibitor, Combined with Ionizing Radiation for Head and Neck Squamous Cell Carcinoma
Justin P. Williams et al.
PLOS ONE (2014)
A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck
A. R. Abdul Razak et al.
ANNALS OF ONCOLOGY (2013)
A phase I, open-label, mass balance study of [14C] dacomitinib (PF-00299804) in healthy male volunteers
Carlo L. Bello et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
A phase II study of intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancer
Krishna Rao et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Promising New Molecular Targeted Therapies in Head and Neck Cancer
Kelly Dorsey et al.
DRUGS (2013)
Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: Rationale for future randomised trials in human papilloma virus-negative disease
Kevin Harrington et al.
EUROPEAN JOURNAL OF CANCER (2013)
Dacomitinib, a new therapy for the treatment of non-small cell lung cancer
Christina Brzezniak et al.
EXPERT OPINION ON PHARMACOTHERAPY (2013)
Head and neck cancer: from anatomy to biology
Pinaki Bose et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial
Athanassios Argiris et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial
Renato G. Martins et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial
Jan B. Vermorken et al.
LANCET ONCOLOGY (2013)
Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to Cetuximab
Ferdows Ather et al.
PLOS ONE (2013)
The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers
Carlo L. Bello et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Tumor Epidermal Growth Factor Receptor and EGFR PY1068 Are Independent Prognostic Indicators for Head and Neck Squamous Cell Carcinoma
Sarah Wheeler et al.
CLINICAL CANCER RESEARCH (2012)
A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Jonas A. de Souza et al.
CLINICAL CANCER RESEARCH (2012)
Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1,-2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors
Toshiaki Takahashi et al.
INVESTIGATIONAL NEW DRUGS (2012)
Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan-Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer
Suresh S. Ramalingam et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer
Hyun-Jin Nam et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study
L. Licitra et al.
ANNALS OF ONCOLOGY (2011)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Combined Modality Treatment With Chemotherapy, Radiation Therapy, Bevacizumab, and Erlotinib in Patients With Locally Advanced Squamous Carcinoma of the Head and Neck A Phase II Trial of the Sarah Cannon Oncology Research Consortium
John D. Hainsworth et al.
CANCER JOURNAL (2011)
Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors
Pasi A. Jaenne et al.
CLINICAL CANCER RESEARCH (2011)
Expression of Amphiregulin and EGFRvIII Affect Outcome of Patients with Squamous Cell Carcinoma of the Head and Neck Receiving Cetuximab-Docetaxel Treatment
Ingeborg Tinhofer et al.
CLINICAL CANCER RESEARCH (2011)
Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
Anil K. Chaturvedi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial
Jean-Pascal Machiels et al.
LANCET ONCOLOGY (2011)
Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: A phase II, randomized, double-blind, placebo-controlled study
Vincent Gregoire et al.
RADIOTHERAPY AND ONCOLOGY (2011)
The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
Nicole G. Chau et al.
HEAD & NECK ONCOLOGY (2011)
PHASE I/II STUDY OF ERLOTINIB COMBINED WITH CISPLATIN AND RADIOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Daniel Herchenhorn et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2010)
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
James A. Bonner et al.
LANCET ONCOLOGY (2010)
Neoadjuvant Chemotherapy/Gefitinib Followed by Concurrent Chemotherapy/Radiation Therapy/Gefitinib for Patients With Locally Advanced Squamous Carcinoma of the Head and Neck
John D. Hainsworth et al.
CANCER (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Phase III Study of Gefitinib 250 Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck
J. Simon W. Stewart et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study
Ezra E. W. Cohen et al.
LANCET ONCOLOGY (2009)
Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin
Melarkode S. Ramakrishnan et al.
MABS (2009)
A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck
Francesco Caponigro et al.
ANTI-CANCER DRUGS (2008)
Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor
Andrea J. Gonzales et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib
Jeffrey A. Engelman et al.
CANCER RESEARCH (2007)
Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC)
R. Hitt et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A Princess Margaret Hospital Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group study
Lillian L. Siu et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy
Jan B. Vermorken et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting
John C. Sok et al.
CLINICAL CANCER RESEARCH (2006)
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
JA Bonner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications
Michel Zimmermann et al.
RADIATION ONCOLOGY (2006)
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck
D Soulieres et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Phase III comparison of high-dose paclitaxel plus cisplatin plus granulocyte colony-stimulating factor versus low-dose paclitaxel plus cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393
AA Forastiere et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
